Diabetic Neuropathic Pain Treatment Landscape 2024: Comprehensive Insights About 10+ Companies and 12+ Pipeline Drugs - Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Diabetic Peripheral Neuropathy Therapeutics Research 2024: Comprehensive Insights about 10+ Companies and 15+ Pipeline Drugs [Yahoo! Finance]
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association [Yahoo! Finance]